yk-fh312

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2006 (NCT00511368)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
Mol. weight
584.84 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-o-(3',3'-dimethylsuccinyl)betulinic acid
  • bevirimat
  • bevirimat
  • bevirimat
  • bevirimat
  • bevirimat
  • bevirimat dimeglumine
  • bevirimat dimeglumine
  • bevirimat dimeglumine
  • dsb*2nmg
  • dsb*2nmg
  • mpc-4326
  • mpc-4326
  • mpc-4326
  • pa-103001
  • pa-103001
  • pa103001-01
  • pa103001-01
  • pa103001-04
  • pa103001-04
  • pa 457
  • pa-457
  • pa-457
  • pa-457
  • pa-457
  • pa-457 di-nmg
  • pa-457 di-nmg
  • pa-457n
  • pa-457n
  • yk-fh312
  • yk-fh312

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01026727Phase 2Nov 1, 2009Myrexis Inc.
NCT01097070Phase 2Nov 1, 2008AIDS Research Consortium of Atlanta, Community Research Initiative of New England, Myrexis Inc., Quest Clinical Research
NCT00967187Phase 2May 1, 2008Myrexis Inc.
NCT00511368Phase 2Apr 1, 2006Myrexis Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Myrexis Inc.For profit4412006
AIDS Research Consortium of AtlantaAcademic/Hospital1012008
Community Research Initiative of New EnglandAcademic/Hospital1012008
Quest Clinical ResearchFor profit1012008
4 organizations
Page 1 / 1